Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
144 Leser
Artikel bewerten:
(0)

Research and Markets - Global Human Embryonic Stem Cells (hESC) Market Analysis 2014-2017 & 2025: Key Players are CellGenix, International Stem Cell, Thermo Fisher Scientific, Kite Pharma, PromoCell and Lonza

DUBLIN, May 1, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Human Embryonic Stem Cells (hESC) Market Analysis By Application (Regenerative Medicines, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Country (U.S., UK, Germany, Japan, China), And Segment Forecasts, 2014 - 2025" report to their offering.

Research and Markets Logo

The global human embryonic stem cells (hESCs) market is anticipated to reach USD 1.06 billion by 2025

Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.

Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.

In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.

Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.

However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.


Further Key Findings from the Report Suggest:

  • hESC derivation provides a unique opportunity for early human development studies
  • It is believed to hold a substantial potential for regenerative medicine and biopharma
  • Differentiated derivatives of these cells are applicable for screening assays in development of novel pharmaceutical moieties
  • Screening for mutagenic as well as toxic compounds can also be carried out using such derivatives
  • Presence of lack of suitable donor organs and tissues for regenerative medicine is expected to increase the demand thus influencing growth
  • Stem cell research is anticipated to exhibit fastest growth amongst the other applications
  • However, presence of controversies pertaining to their use as a consequence of ethical considerations is responsible for steady growth
  • Europe accounts for considerable share of the market, following North America
  • As per a recent survey carried out by Swiss government, citizens there are more willing to accept embryonic stem cell research than politicians
  • Asia Pacific is anticipated to drive market with fastest YoY growth
  • Rising awareness amongst the population and physicians with respect to associated therapies is anticipated to propel progress
  • Key players contributing in this market are CellGenix GmbH, International Stem Cell Corporation, Thermo Fisher Scientific, Inc.; Kite Pharma, PromoCell GmbH, and Lonza
  • Presence of clinical trial pipeline for embryonic stem cell derived therapy for targeting different diseases is expected to fuel growth.
  • The diseases targeted include macular degeneration, Parkinson's disease, type I diabetes mellitus, and spinal cord injury.

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 Human Embryonic Stem Cells Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Technological advancement involving stem cells therapy
3.1.1.2 Rising demand for regenerative medicines
3.1.1.3 R&D in toxicology testing
3.1.1.4 Technological advanvcements for the production of embryonic stem cells through alternative methods
3.1.1.5 Increasing prevalence of genetic disorders
3.1.2 Market Restraint Analysis
3.1.2.1 Ethical concern related to stem cell research
3.2 Penetration & Growth Prospect Mapping for Application, 2015
3.3 Human embryonic stem cells -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter's

4 Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis
4.1 Global Human Embryonic Stem Cells Market: Application Movement Analysis
4.2 Regenerative Medicine
4.3 Stem Cell Biology Research
4.4 Tissue Engineering
4.5 Toxicology Testing

5 Human Embryonic Stem Cells Market: Regional Estimates & Trend Analysis, by Application

6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles

  • Astellas Pharma Inc/ Ocata Therapeutics
  • STEMCELL Technologies Inc.
  • BIOTIME, INC. / Cell Cure Neurosciences LTD
  • Thermo Fisher Scientific, Inc.
  • CellGenix GmbH
  • ESI BIO
  • PromoCell GmbH
  • Lonza
  • Kite Pharma
  • Cynata
  • Sumanas, Inc.
  • LifeCell
  • International Stem Cell Corporation
  • Cordlife
  • Genea BioCells
  • Geron

For more information about this report visit http://www.researchandmarkets.com/research/cnx9vb/human_embryonic


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.